845 related articles for article (PubMed ID: 35319762)
21. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
23. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
[TBL] [Abstract][Full Text] [Related]
24. Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021.
Miele K; Kim SY; Jones R; Rembert JH; Wachman EM; Shrestha H; Henninger ML; Kimes TM; Schneider PD; Sivaloganathan V; Sward KA; Deshmukh VG; Sanjuan PM; Maxwell JR; Seligman NS; Caveglia S; Louis JM; Wright T; Bennett CC; Green C; George N; Gosdin L; Tran EL; Meaney-Delman D; Gilboa SM
MMWR Surveill Summ; 2023 May; 72(3):1-14. PubMed ID: 37130060
[TBL] [Abstract][Full Text] [Related]
25. Racial and ethnic disparities in medication for opioid use disorder access, use, and treatment outcomes in Medicare.
Gibbons JB; McCullough JS; Zivin K; Brown ZY; Norton EC
J Subst Use Addict Treat; 2024 Feb; 157():209271. PubMed ID: 38135120
[TBL] [Abstract][Full Text] [Related]
26. Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder.
Cook RR; Jaworski EN; Hoffman KA; Waddell EN; Myers R; Korthuis PT; Vergara-Rodriguez P
Subst Abus; 2023 Oct; 44(4):301-312. PubMed ID: 37842910
[TBL] [Abstract][Full Text] [Related]
27. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
28. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
29. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
30. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
31. Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
Krawczyk N; Garrett B; Ahmad NJ; Patel E; Solomon K; Stuart EA; Saloner B
Drug Alcohol Depend; 2021 Mar; 220():108512. PubMed ID: 33508692
[TBL] [Abstract][Full Text] [Related]
32. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
33. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
[TBL] [Abstract][Full Text] [Related]
34. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
35. Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.
Busch AB; Greenfield SF; Reif S; Normand ST; Huskamp HA
J Subst Abuse Treat; 2020 Aug; 115():108040. PubMed ID: 32600627
[TBL] [Abstract][Full Text] [Related]
36. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
Cook RR; Foot C; Arah OA; Humphreys K; Rudolph KE; Luo SX; Tsui JI; Levander XA; Korthuis PT
Addict Sci Clin Pract; 2023 Feb; 18(1):11. PubMed ID: 36788634
[TBL] [Abstract][Full Text] [Related]
37. Racialized and beneficiary inequities in medication to treat opioid use disorder receipt within the US Military Health System.
Lance Tippit T; O'Connell MA; Costantino RC; Scott-Richardson M; Peters S; Pakieser J; Tilley LC; Highland KB
Drug Alcohol Depend; 2023 Dec; 253():111025. PubMed ID: 38006670
[TBL] [Abstract][Full Text] [Related]
38. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
39. Integrating Opioid Use Disorder Treatment Into Primary Care Settings.
Austin EJ; Chen J; Briggs ES; Ferro L; Barry P; Heald A; Merrill JO; Curran GM; Saxon AJ; Fortney JC; Ratzliff AD; Williams EC
JAMA Netw Open; 2023 Aug; 6(8):e2328627. PubMed ID: 37566414
[TBL] [Abstract][Full Text] [Related]
40. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
